Mitral Valve, Double Orifice
|
|
|
INTRODUCTION
Background: Double orifice
mitral valve (DOMV) is an uncommon anomaly of surgical importance
characterized by a mitral valve with a single fibrous annulus with 2
orifices opening into the left ventricle (LV). Subvalvular structures,
especially the tensor apparatus, invariably show varying degrees of
abnormality. While DOMV may allow normal hemodynamic flow between the left
atrium and LV, it can significantly obstruct mitral valve inflow or mitral
valve incompetence. When either stenosis or incompetence is severe,
surgical correction is necessary. Preoperative recognition of DOMV and an
awareness of the associated anatomic variations are important to achieve
good surgical correction.
Pathophysiology: The normal
mitral valve consists of a large central orifice located between a large
sail-like anterior leaflet and a smaller C-shaped posterior leaflet, while
in DOMV the orifice is divided into 2 parts by abnormal tissue. Three
major types of DOMV are recognized, as follows:
- Eccentric or hole type: This is the most
common variety (about 85% of all patients) and is characterized by a
small accessory orifice situated at either the anterolateral or
posteromedial commissure. Other anomalies of the valve apparatus, such
as cleft leaflets, accessory papillary muscles, fused papillary
muscles, and crossing chordae tendineae, commonly are present. When
the accessory orifice is located at the posteromedial commissure, a
common atrioventricular canal usually is present. Conversely, the
atrioventricular canal normally is divided if the accessory orifice is
located at the anterolateral commissure.
- Central or bridge type: In about 15% of
patients with DOMV, a central bridge of fibrous or abnormal leaflet
tissue connects the 2 leaflets of the mitral valve, dividing the
orifice into medial and lateral parts. These 2 openings may be equal
or unequal, and papillary muscles usually are normal with chordae
surrounding each orifice inserting into 1 papillary muscle.
- Duplicate mitral valve: This has 2 mitral
valve annuli and valves, each with its own set of leaflets,
commissures, chordae, and papillary muscles.
The combined area of DOMV in the presence of an
atrioventricular canal defect ranges from 85-90% of normal expected area;
however, in the absence of an associated atrioventricular defect, the
combined area may be significantly less than normal. Reduction in the
effective valve area is caused by the abnormal structure, including large
bridging tissue, bulky abnormal leaflets, fused chordae, or abnormal
papillary muscles.
Associated congenital heart defects are common,
although DOMV can occur as an isolated anomaly. The most common associated
lesion is common atrioventricular canal defect (endocardial cushion
defect). Other lesions include ventricular septal defect, coarctation of
aorta, interrupted aortic arch, subaortic stenosis, patent ductus
arteriosus, and primum atrial septal defect. Occasionally, DOMV is
observed with secundum atrial septal defect, tetralogy of Fallot,
hypoplastic left heart syndrome, Ebstein anomaly of tricuspid valve,
dysplastic tricuspid valve, parachute mitral valve, truncus arteriosus,
pulmonary stenosis, or bicuspid aortic valve.
The mitral valve can function reasonably well in
about 50% of all patients with DOMV. In the remaining patients, it can
cause significant mitral stenosis (MS) or mitral regurgitation (MR).
Mitral stenosis
Obstruction to mitral valve inflow results from a
reduction in the total mitral valve area. When MS is significant, a
diastolic pressure difference builds up between the left atrium and LV.
The rise in left atrial and pulmonary venous pressure leads to exudation
of fluid into the interstitium of the lung and increased pulmonary
stiffness (the main cause of breathlessness). In severe cases, frank
pulmonary edema develops.
Persistent pulmonary venous hypertension leads to
pulmonary arterial hypertension, a rise in pulmonary vascular resistance,
and, eventually, failure of the right ventricle (RV) with tricuspid
regurgitation.
Mitral regurgitation
About 25% of patients with DOMV present with MR
as the dominant hemodynamic abnormality, especially when it is associated
with an atrioventricular canal defect. Similar to MS, MR also causes left
atrial and pulmonary venous hypertension. Clinical effects depend upon the
severity and duration of MR. LV outflow obstruction from associated
subaortic stenosis or coarctation can aggravate MR. With increasing MR,
cardiac output is maintained by increasing LV diastolic volume and
hypertrophy. In chronic MR, LV function deteriorates, leading to further
worsening of pulmonary venous congestion, pulmonary hypertension, and
right heart failure. Ventricular dysfunction secondary to chronic
dilatation often is irreversible even after correction of the primary
mitral lesion. The left atrium tends to enlarge markedly in MR and may
cause pressure effects on the left bronchus.
Frequency:
- Internationally: No data are
available on the incidence of DOMV. Approximately 50% of all cases of
DOMV are detected during investigation of other congenital heart
diseases (CHDs). More than 100 cases of DOMV are reported in the
English literature.
CLINICAL
History:
- DOMV is detected in 1 of the following 3 ways:
- Most commonly, DOMV is diagnosed as an
associated lesion with other congenital heart defects. Thus,
pulmonary congestion and heart failure from a common
atrioventricular canal or ventricular septal defect (VSD) are
aggravated by an abnormal mitral valve. Conversely, conditions such
as tetralogy of Fallot reduce the mitral valve flow and mask the
presence of DOMV. In such patients, DOMV is not detected unless
specifically looked for.
- DOMV may be detected as the anatomic cause
when investigating patients, especially at a young age, for
symptomatic mitral valve disease.
- Occasionally, DOMV is an incidental finding
in asymptomatic patients who undergo echocardiography for any
reason.
- Symptoms of DOMV: The severity of symptoms
depends upon the degree of left atrial hypertension. Common symptoms
include 1 or more of the following:
- Dyspnea, nocturnal cough, and tachypnea
occur from pulmonary venous congestion and increased lung stiffness.
- Frequent respiratory infections and wheezing
occur from pulmonary congestion, increased fluid exudation, and
airway narrowing.
- Poor feeding, failure to thrive, fatigue,
and sweating occur because of heart failure and reduced cardiac
output.
- Occasionally, the child with DOMV can
present with acute pulmonary edema or generalized edema.
- Hemoptysis and syncope can occur in older
patients with DOMV.
Physical:
- Physical signs in DOMV with MS
- Children with severe MS often are quite ill
with respiratory distress, tachypnea, and subcostal recession.
- Reduced pulse volume and peripheral cyanosis
indicate diminished cardiac output and poor tissue perfusion.
- Central cyanosis can develop in the presence
of pulmonary edema.
- Jugular venous pressure rises with the onset
of right heart failure.
- Palpation reveals a parasternal heave from
the hypertrophied RV and, occasionally, a diastolic thrill at the
apex.
- The first heart sound may be normal or
accentuated, while the pulmonary second sound generally is loud
because of pulmonary hypertension. Unlike acquired MS, an opening
snap is not commonly heard.
- A low-pitched mid diastolic murmur of
varying intensity is audible at the mitral area. It often is heard
best in the left lateral decubitus and is especially loud when MS is
associated with a VSD or mitral regurgitation.
- In chronic severe MS, signs of tricuspid
incompetence, such as systolic expansile pulsation in the jugular
vein and liver and a pansystolic murmur at the lower sternal border,
appear. This murmur typically accentuates on inspiration.
- Physical signs in DOMV with MR
- The child with severe MR can present with
respiratory distress and pulmonary edema.
- The pulse often is brisk, while the apical
impulse is displaced downwards and outwards and has a hyperdynamic
quality because of LV hypertrophy.
- The first and second heart sounds usually
are normal in intensity, though the second heart sounds may be
widely split. A third heart sound is common at the apex.
- A blowing pansystolic murmur is heard at or
just inside the apex and often is conducted towards the sternum
rather than towards the axilla.
- Severe MR can cause a low-pitched apical
diastolic murmur from large diastolic flow across the mitral valve.
- Pulmonary hypertension and tricuspid
incompetence can occur in MR, though not as commonly or as severely
as in MS.
DIFFERENTIALS
Cor Triatriatum
Mitral Stenosis, Supravalvular Ring
Mitral Valve Insufficiency
Other Problems to be Considered:
Mitral stenosis, valvar
Pulmonary hypertension, congenital heart disease
|
WORKUP
Lab Studies:
- Investigate to quantify the hemodynamic
abnormality and to define the valve anatomy before undertaking
surgical treatment.
- No specific laboratory blood tests are
required for diagnosis.
Imaging Studies:
- Diagnose left atrial enlargement (the most
common abnormality in DOMV) if straightening of the left upper
cardiac border (mitralization), widening of the tracheal carina, and
elevation of the left bronchus are present. In older children, the
enlarged left atrium can be observed as a double density near the
right atrial border, tending to enlarge in a posterior direction. A
barium-swallow study of the esophagus in lateral projection shows a
rounded indentation of the anterior wall. Mitral incompetence, if
severe, causes LV enlargement.
- Prominent upper lobe veins, increased
interstitial markings, and Kerley lines indicate pulmonary venous
hypertension. In severe cases, alveolar edema produces a hazy
appearance in the hilar regions of both lung fields. The pulmonary
trunk and its branches become dilated with the rise in pulmonary
arterial pressure.
- Two-dimensional echocardiography with
Doppler is the most important tool for diagnosis and detailed
assessment of patients with DOMV.
- Systematically examine the mitral valve
using multiple views for imaging and Doppler interrogation. Pay
particular attention to evaluate all components of the mitral valve
apparatus.
- The 2 orifices in DOMV are observed best in
a cross-sectional view of the LV in short axis, scanning the
ventricle from the apex to the base. Apical and subcostal 4-chamber
views also are useful to visualize the subvalvular apparatus.
- Identify the relative positions of the 2
openings and measure the area. Carefully study the nature and size
of the bridging tissue and leaflets. Any associated congenital heart
defect also may be identified and quantified.
- Look for and measure the enlargement of the
left atrium, LV, RV, and pulmonary artery on 2-dimensional
echocardiography.
- M-mode echocardiography of the pulmonary
valve often shows signs of pulmonary hypertension such as an
abbreviated "a” wave, midsystolic closure, and systolic
flutter of the pulmonary leaflets.
- Doppler study and color flow mapping are
useful to show the pattern of flow through the mitral valve.
- Assess severity of mitral regurgitation in a
semiquantitative manner from the area of the regurgitant jet in the
left atrium.
- The severity of mitral obstruction can be
quantified by measuring the mean velocity of diastolic flow through
the mitral valve; the mean diastolic velocity and the pressure
half-time (time taken for the peak diastolic velocity to fall to
half its initial value) correlate well with severity of MS.
- Obtain a good estimate of the systolic
pulmonary artery pressure by measuring the peak velocity of the
tricuspid regurgitant jet in the right atrium.
- Transesophageal echocardiography
- Transesophageal echocardiography generally
is not necessary in children to assess DOMV because adequate
information may be obtained from transthoracic windows.
- In older patients, especially in heavy
individuals or patients with emphysematous chests, transesophageal
study can provide clear visualization of all valve components.
- Thrombi in the left atrium can be detected.
- At all ages, transesophageal
echocardiography performed intraoperatively is extremely useful to
assess adequacy of mitral valve repair in the operating room.
Other Tests:
- Sinus rhythm commonly is present.
Occasionally, atrial flutter or atrial fibrillation can develop in
patients with DOMV with chronic left atrial dilatation.
- Left atrial enlargement occurs in most
patients with DOMV and is diagnosed by wide bifid P waves (P mitral
pattern) in limb leads and/or increased P terminal force in lead V1.
- Tall peaked P waves in inferior leads
indicate right atrial hypertrophy because of pulmonary hypertension
and tricuspid incompetence.
- The mean frontal plane QRS axis may be
normal or shifted to the right.
- RV hypertrophy is common in stenotic DOMV,
while mitral incompetence is associated with LV hypertrophy.
- Electrocardiographic findings may be
modified by the presence of associated congenital heart defects.
Procedures:
- Cardiac catheterization often is necessary
to quantify the hemodynamic effects of abnormal mitral valve
function.
- DOMV with obstruction is characterized by
elevation of left atrial pressure. Pressure tracings obtained from
the pulmonary artery wedge position reflect left atrial pressure and
avoid the need to enter the left atrium by puncturing the
interatrial septum. Simultaneous pressure recording shows pulmonary
artery wedge pressure is significantly higher than LV pressure
throughout diastole.
- In patients with mitral regurgitation, the
left atrial and pulmonary artery wedge pressures are elevated, but
no gradient can be demonstrated across the mitral valve at end of
diastole; LV diastolic pressure often is increased.
- Cardiac output and vascular resistance may
be measured; associated shunts and obstructive lesions, if any, also
may be identified and measured at cardiac catheterization.
- With the availability of high-quality
echocardiography, cardiac angiography has a limited role in the
assessment of DOMV. Echocardiography is superior to angiography in
defining anatomic and functional valve abnormalities.
- LV angiography may be performed to confirm
the severity of MR and to assess LV function.
- Cardiac angiography also is important to
assess other associated defects.
TREATMENT
Medical Care: General principles
of management
Patients with DOMV can be evaluated as
outpatients. Admit to the hospital for cardiac catheterization, treatment
of severe heart failure or pulmonary edema, and for surgical treatment.
Management depends upon the type and severity of
mitral valve dysfunction. Isolated DOMV causing neither obstruction nor
regurgitation needs no active intervention; however, provide long-term
follow-up care in these patients to detect the onset of hemodynamic
problems or complications.
All patients with significant degrees of MS or
regurgitation require medical and, possibly, surgical treatment.
- Use medical therapy for initial
stabilization and to relieve pulmonary edema.
- Control congestive heart failure (CHF) while
awaiting detailed assessment and surgical repair.
- Use medical therapy as an adjunct to
surgical repair in the postoperative period.
- Medical therapy may be the only option in
small infants. Control of CHF may defer surgery until the child
grows to an appropriate age and size.
- Adjunctive therapy
- Administer potassium supplements to all
patients receiving frusemide or thiazide diuretics.
- Restrict physical activity in symptomatic
patients.
- Treat patients with severe pulmonary
venous congestion in a sitting or propped-up position.
- Administer parenteral morphine in patients
with pulmonary edema to help relieve anxiety and reduce pulmonary
congestion.
- Administer oxygen by a nasal catheter or
mask to improve oxygenation in acute pulmonary edema.
- Vigorously treat concurrent infections or
other aggravating factors.
- Correcting anemia, if present, is
important. Increasing the oxygen-carrying capacity by a
packed-cell transfusion in patients with severe symptoms or heart
failure may provide considerable relief.
- All patients with DOMV need antibiotic
prophylaxis against infective endocarditis when they undergo any
dental or surgical procedure.
Surgical Care:
- The principles of surgical treatment of DOMV
are to correct abnormal mitral valve function in DOMV.
- Perform surgical repair in all symptomatic
patients with DOMV and significant degrees of MS or mitral
regurgitation.
- Perform early operation for DOMV in the
presence of intractable heart failure or pulmonary edema, pulmonary
arterial hypertension, worsening LV function, or a progressive
increase in heart size from ventricular dilatation.
- Adjust the type of operation, depending upon
anatomic abnormality in the mitral valve apparatus. Make every effort
to define the anatomy in detail before undertaking surgery. In many
patients, the valve may be amenable to repair and reconstruction;
however, if the valve mechanism is markedly abnormal, mitral valve
replacement is necessary.
- Selected cases of DOMV with MS may be amenable
to balloon dilatation.
Consultations:
Diet:
- Asymptomatic patients with DOMV require no
special diet.
- Counsel patients to avoid excess intake of
salt or reduce salt intake in presence of heart failure. Use salt
restriction cautiously in infants.
- Restrict fluid intake to approximately 60-80
mL/kg/d in infants with CHF.
Activity: Patients with
pulmonary venous congestion or CHF should avoid strenuous exertion.
MEDICATION
Medical therapy for DOMV consists of drugs for
control of CHF. The 3 groups of drugs used are diuretics (to promote
excretion of excess water), positive inotropic drugs (to improve
myocardial contraction), and vasodilators (to reduce arterial resistance).
Drug Category: Diuretics --
Promotes excretion of water and electrolytes by the kidneys. Used to treat
heart failure or hepatic, renal, or pulmonary disease when sodium and
water retention has resulted in edema or ascites. Useful to remove excess
water that accumulates in CHF. Relieve symptoms that are associated with
pulmonary congestion and reduce peripheral edema.
Drug Name
|
Furosemide
(Lasix) -- DOC for rapid relief of pulmonary congestion and edema
from heart failure. Useful for maintenance therapy of CHF in
patients with DOMV. Promotes renal excretion of water by
inhibition of electrolyte transport system in the ascending limb
of the loop of Henle. Increases solute and water excretion, even
in the presence of a declining glomerular filtration rate.
|
| Adult Dose |
20-80
mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states
|
| Pediatric Dose |
2-5
mg/kg/d PO divided bid/tid
1-2 mg/kg/dose IV bid/tid
|
| Contraindications |
Documented
hypersensitivity; hepatic coma, anuria, and state of severe
electrolyte depletion
|
| Interactions |
Antagonizes
muscle relaxing effect of tubocurarine; auditory toxicity appears
to be increased with coadministration of aminoglycosides and
furosemide; hearing loss of varying degrees may occur;
anticoagulant activity of warfarin may be enhanced when
administered concurrently with this medication
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Titrate
dose to achieve optimal diuresis without undue electrolyte
imbalance or other adverse effects; monitor serum electrolyte
levels at periodic intervals; observe for dehydration, hypokalemia,
hyponatremia, hypochloremic alkalosis, hyperuricemia,
hypomagnesemia, and sensorineural hearing loss |
Drug Name
|
Chlorothiazide
(Diuril) -- Causes increased excretion of water by inhibiting
reabsorption of sodium chloride in the distal renal tubule. Less
potent than furosemide, thiazide diuretics are useful in
maintenance therapy of CHF. In severe heart failure or refractory
edema, thiazides act synergistically with furosemide to promote
diuresis.
|
| Adult Dose |
125-500
mg/d PO qd or divided bid
|
| Pediatric Dose |
20
mg/kg/d PO divided bid
|
| Contraindications |
Documented
hypersensitivity; anuria or renal decompensation
|
| Interactions |
May
decrease effects of anticoagulants, antigout agents, and
sulfonylureas; may increase toxicity of allopurinol, anesthetics,
antineoplastics, calcium salts, loop diuretics, lithium, diazoxide,
digitalis, amphotericin B, and nondepolarizing muscle relaxants
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Monitor
serum electrolyte levels at periodic intervals; observe for
hypokalemia, hyponatremia, hypochloremic alkalosis, hyperuricemia,
hypomagnesemia, hypercalcemia, hyperglycemia, rise in serum LDL
cholesterol and triglyceride levels, and pancreatitis |
Drug Name
|
Hydrochlorothiazide
(Esidrix, HydroDIURIL) -- Causes increased excretion of water by
inhibiting reabsorption of sodium chloride in the distal renal
tubule. Less potent than furosemide. Useful in maintenance therapy
of CHF. In severe heart failure or refractory edema, thiazides act
synergistically with furosemide to promote diuresis.
|
| Adult Dose |
12.5-50
mg/d PO divided bid; not to exceed 200 mg/kg/d
|
| Pediatric Dose |
2 mg/kg/d
PO divided bid
|
| Contraindications |
Documented
hypersensitivity; anuria or renal decompensation
|
| Interactions |
May
decrease effects of anticoagulants, antigout agents, and
sulfonylureas; may increase toxicity of allopurinol, anesthetics,
antineoplastics, calcium salts, loop diuretics, lithium, diazoxide,
digitalis, amphotericin B, and nondepolarizing muscle relaxants
|
| Pregnancy |
B -
Usually safe but benefits must outweigh the risks.
|
| Precautions |
Monitor
serum electrolyte levels at periodic intervals; observe for
hypokalemia, hyponatremia, hypochloremic alkalosis, hyperuricemia,
hypomagnesemia, hypercalcemia, hyperglycemia, rise in serum LDL
cholesterol and triglyceride levels, and pancreatitis |
Drug Name
|
Spironolactone
(Aldactone) -- Counteracts secondary hyperaldosteronism that
occurs in cardiac failure. Inhibits sodium absorption in the
collecting duct. Has a potassium-sparing diuretic effect. Used
alone, it produces relatively mild diuresis. Can be used in
conjunction with furosemide for synergistic action in severe CHF.
|
| Adult Dose |
25-100
mg/d PO divided bid
|
| Pediatric Dose |
2-4
mg/kg/d PO divided bid
|
| Contraindications |
Documented
hypersensitivity; anuria, renal failure, or hyperkalemia
|
| Interactions |
May
decrease effect of anticoagulants; potassium and potassium sparing
diuretics may increase toxicity of spironolactone
|
| Pregnancy |
D -
Unsafe in pregnancy
|
| Precautions |
Renal and
hepatic impairment; monitor serum potassium level; special care
combination with captopril; observe for hyperkalemia, metabolic
acidosis, rash, and gynecomastia |
Drug Category: Inotropic agents
-- Positive inotropic agents increase the force of contraction of
the myocardium and are used to treat acute and chronic CHF. Some may also
increase or decrease the heart rate (ie, positive or negative chronotropic
agents), provide vasodilatation, or improve myocardial relaxation. These
additional properties influence the choice of drug for specific
circumstances.
Drug Name
|
Digoxin (Lanoxin)
-- DOC to improve cardiac failure by a positive inotropic effect
on the myocardium. Helps to control fast ventricular rate,
especially in the presence of atrial arrhythmia.
Preparations commonly used for pediatric patients include tablets
(0.125 mg, 0.25 mg) or elixir (0.05 mg/mL). Capsules and a
parenteral injection are also available.
|
| Adult Dose |
Total
digitalizing dose (TDD): 1-1.5 mg PO in divided doses over 1 d
Maintenance dose: 0.125-0.375 mg/d PO qd or divided bid
|
| Pediatric Dose |
TDD:
Premature infants: 0.02 mg/kg PO divided q8h
Full-term infants: 0.03 mg/kg PO divided q8h
1-24 months: 0.04-0.05 mg/kg PO divided q8h
>2 years: 0.03-0.04 mg/kg PO divided q8h
Maintenance dose:
Infants: 6-8 mcg/kg/d PO
2-5 years: 10-15 mcg/kg/d PO
5-10 years: 7-10 mcg/kg/d PO
>10 years: 3-5 mcg/kg/d PO
<10 years: Recommend daily maintenance dose be divided bid
|
| Contraindications |
Documented
hypersensitivity; beriberi heart disease, idiopathic hypertrophic
subaortic stenosis, constrictive pericarditis, and carotid sinus
syndrome
|
| Interactions |
Medications
that may increase digoxin levels include alprazolam,
benzodiazepines, bepridil, captopril, cyclosporine, propafenone,
propantheline, quinidine, diltiazem, aminoglycosides, PO
amiodarone, anticholinergics, diphenoxylate, erythromycin,
felodipine, flecainide, hydroxychloroquine, itraconazole,
nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol,
tetracycline, tolbutamide, and verapamil
Medications that may decrease serum digoxin levels include
aminoglutethimide, antihistamines, cholestyramine, neomycin,
penicillamine, aminoglycosides, PO colestipol, hydantoins,
hypoglycemic agents, antineoplastic treatment combinations
(including carmustine, bleomycin, methotrexate, cytarabine,
doxorubicin, cyclophosphamide, vincristine, procarbazine),
aluminum or magnesium antacids, rifampin, sucralfate,
sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic
acid
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Hypokalemia
may reduce positive inotropic effect of digitalis; IV calcium may
produce arrhythmias in digitalized patients; hypercalcemia
predisposes patient to digitalis toxicity, and hypocalcemia can
make digoxin ineffective until serum calcium levels are normal;
institute magnesium replacement therapy in patients with
hypomagnesemia to prevent digitalis toxicity; patients diagnosed
with incomplete AV block may progress to complete block when
treated with digoxin; hypothyroidism, hypoxia, and acute
myocarditis |
Drug Category: Vasodilators --
Drugs that produce vasodilation include angiotensin converting enzyme
(ACE) inhibitors, nitrates, and direct vasodilators (eg, hydralazine), of
these drug classes, ACE inhibitors are frequently used, as their adverse
effects are the most tolerated. They reduce afterload on the LV by
decreasing systemic arterial resistance. Particularly helpful in patients
with MR, in whom a fall in afterload leads to a decrease in the severity
of regurgitation and improves ventricular function. DOC is captopril.
Newer drugs from this category such as enalapril and lisinopril also are
used for treatment of CHF, but experience with their use in children is
limited.
Drug Name
|
Captopril
(Capoten) -- Prevents conversion of angiotensin I to angiotensin
II, a potent vasoconstrictor, resulting in lower aldosterone
secretion.
|
| Adult Dose |
25-150
mg/d PO divided tid; not to exceed 150 mg tid
|
| Pediatric Dose |
0.1–0.5
mg/kg/dose PO tid; may gradually increase to a maximum of 6
mg/kg/d PO divided tid
|
| Contraindications |
Documented
hypersensitivity; renal impairment
|
| Interactions |
NSAIDs
may reduce hypotensive effects of captopril; ACE inhibitors may
increase digoxin, lithium, and allopurinol levels; rifampin
decreases captopril levels; probenecid may increase captopril
levels; the hypotensive effects of ACE inhibitors may be enhanced
when administered concurrently with diuretics
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Pregnancy
category D in second or third trimester; caution in renal
impairment, valvular stenosis, or severe CHF; initiate at low
doses and gradually increase according to blood pressure, patient
tolerance, and clinical effects; observe for hypotension, rash,
cough, dizziness, fatigue, hyperkalemia, hypoglycemia, uremia,
proteinuria, and neutropenia |
Drug Name
|
Enalapril
(Vasotec) -- Competitive inhibitor of ACE. Reduces angiotensin II
levels, decreasing aldosterone secretion.
|
| Adult Dose |
5-30 mg/d
PO divided bid
|
| Pediatric Dose |
0.2–0.5
mg/kg/d PO divided bid
|
| Contraindications |
Documented
hypersensitivity; renal impairment
|
| Interactions |
NSAIDs
may reduce hypotensive effects of captopril; ACE inhibitors may
increase digoxin, lithium, and allopurinol levels; rifampin
decreases captopril levels; probenecid may increase captopril
levels; the hypotensive effects of ACE inhibitors may be enhanced
when administered concurrently with diuretics
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Pregnancy
category D in second or third trimester; caution in renal
impairment, valvular stenosis, or severe CHF; initiate at low
doses and gradually increase according to blood pressure, patient
tolerance, and clinical effects; observe for hypotension, rash,
cough, dizziness, fatigue, hyperkalemia, hypoglycemia, uremia,
proteinuria, and neutropenia |
Drug Name
|
Lisinopril
(Zestril, Prinivil) -- Prevents conversion of angiotensin I to
angiotensin II, a potent vasoconstrictor, resulting in lower
aldosterone secretion.
|
| Adult Dose |
10-30
mg/d PO divided bid
|
| Pediatric Dose |
Not
established, limited data suggests: 0.2–1 mg/kg/d PO divided bid
|
| Contraindications |
Documented
hypersensitivity; renal impairment
|
| Interactions |
NSAIDs
may reduce hypotensive effects of captopril; ACE inhibitors may
increase digoxin, lithium, and allopurinol levels; rifampin
decreases captopril levels; probenecid may increase captopril
levels; the hypotensive effects of ACE inhibitors may be enhanced
when administered concurrently with diuretics
|
| Pregnancy |
C -
Safety for use during pregnancy has not been established.
|
| Precautions |
Pregnancy
category D in second or third trimester; caution in renal
impairment, valvular stenosis, or severe CHF; initiate at low
doses and gradually increase according to blood pressure, patient
tolerance, and clinical effects; observe for hypotension, rash,
cough, dizziness, fatigue, hyperkalemia, hypoglycemia, uremia,
proteinuria, and neutropenia |
FOLLOW-UP
Further Inpatient Care:
- Hemodynamic study by cardiac catheterization
and angiography
Further Outpatient Care:
- Monitor medications for compliance, dose
requirement, and adverse effects.
- Periodically check for electrolyte
disturbances.
- Provide follow-up care for prompt detection
and treatment of intercurrent infections, arrhythmia, and other
complications.
In/Out Patient Meds:
- Medications for DOMV include diuretics,
digoxin, potassium chloride, and vasodilators.
- Antibiotics are indicated for intercurrent
bacterial infections.
- Counsel patient concerning antibiotic
prophylaxis against infective endocarditis during dental and surgical
procedures.
Transfer:
- Transfer to a tertiary cardiac facility may be
required for further diagnostic evaluation and surgical treatment.
Deterrence/Prevention:
- Symptomatic patients with DOMV should avoid
sports and other strenuous activity that could aggravate pulmonary
congestion and CHF.
Complications:
- Possible complications are MR, MS, pulmonary
edema, recurrent respiratory infection, atrial fibrillation and other
atrial arrhythmias, infective endocarditis, left atrial thrombus, and
pulmonary arterial hypertension.
Prognosis:
- Isolated DOMV is a rare but correctable
defect, if the abnormality is recognized and appropriately treated.
- When DOMV is associated with other congenital
heart defects the long-term outcome depends upon the major cardiac
abnormality.
Patient Education:
- Impose activity restrictions on symptomatic
patients.
- Advise the patient concerning the need for
periodic medical review.
- Inform the patient regarding prophylaxis for
infective endocarditis and prompt attention to all infections.
- Counsel the patient about the need for
regular anticoagulant therapy with coumadin in those who undergo
valve replacement.
MISCELLANEOUS
Medical/Legal Pitfalls:
- Failure to identify DOMV as the cause of
mitral valve obstruction or regurgitation
- Failure to identify DOMV as an associated
defect in patients with atrioventricular canal defect and other CHDs
- Failure to recognize associated abnormalities
of the mitral valve apparatus in patients with DOMV
Special Concerns:
- DOMV may not be detected easily in children
with CHD; therefore, awareness of the problem and careful
echocardiographic screening are important in all children with mitral
valve disease.
PICTURES
| Caption:
Picture 1. Mitral valve, double orifice. Two-dimensional
echocardiogram in parasternal short-axis view showing 2 mitral
valve orifices. |
 |
| Picture Type:
Photo |
| Caption:
Picture 2. Mitral valve, double orifice. Two-dimensional
echocardiogram of the mitral valve in apical view with color flow
mapping, showing diastolic flow through 2 separate orifices. |
 |
| Picture Type:
Photo |
|